Roche Reports Phase 3 extension Data for Evobrutinib in Myasthenia gravis

Roche today announced Phase 3 extension results for Evobrutinib in patients with Myasthenia gravis. The study demonstrated that Evobrutinib demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Myasthenia gravis and support the continued development of Evobrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Evobrutinib was consistent with previous observations, with no new safety signals identified.